Opinion

Luciano J Costa: S-MRD Negativity and Stopping Therapy Have Less Than 10% Risk of Progression or MRD Resurgence in 4 Years

Luciano Costa/LinkedIn

Jun 18, 2025, 10:35

Luciano J Costa: S-MRD Negativity and Stopping Therapy Have Less Than 10% Risk of Progression or MRD Resurgence in 4 Years

Luciano J Costa, Professor at University of Alabama at Birmingham, reshared his post on X, adding:

“Patients with standard risk Multiple Myeloma treated with QUADs + ASCT, achieving S-MRD negativity and stopping therapy have <10% risk of progression or MRD resurgence in 4 years!”

Quoting his original post:

“Optimal MRD-based end point to support response-adapted treatment cessation in NDMM.”

Title: Optimal MRD-based end point to support response-adapted treatment cessation in NDMM

Authors: Smith Giri, Binod Dhakal, Natalie S Callander, Eva Medvedova, Kelly Godby, Bhagirathbhai Dholaria, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca Silbermann, Luciano J. Costa

Read Full Article.

Luciano J Costa

More posts featuring Luciano J Costa on OncoDaily.

Bhagirathbhai Dholaria Binod Dhakal cancer Eva Medvedova Gayathri Ravi Kelly Godby Luciano J Costa MRD-Guided Therapy multiple myeloma Natalie S Callander OncoDaily Oncology Rebecca Silbermann Saurabh Chhabra Smith Giri Susan Bal

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care